Compass Therapeutics Inc. (CMPX)
Compass Therapeutics Statistics
Share Statistics
Compass Therapeutics has 138.28M shares outstanding. The number of shares has increased by 0.5% in one year.
| 138.28M |
| 0.5% |
| 0.5% |
| 73.68% |
| 87.95M |
| 84 |
| 0.01% |
Short Selling Information
The latest short interest is 7.43M, so 5.4% of the outstanding shares have been sold short.
| 7.43M |
| 5.4% |
| 7.64% |
| 13.63 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Compass Therapeutics.
| n/a |
| n/a |
| n/a |
| n/a |
Financial Position
The company has a current ratio of 14.96, with a Debt / Equity ratio of 0.05.
| 14.96 |
| 14.96 |
| 0.05 |
| -0.12 |
| -0.15 |
| 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| n/a |
| n/a |
| n/a |
| $24,285.71 |
| $-1,410,714.29 |
| 35 |
| 0.01 |
| n/a |
Taxes
| n/a |
| 0% |
Stock Price Statistics
The stock price has increased by 116.67% in the last 52 weeks. The beta is 1.22, so Compass Therapeutics's price volatility has been higher than the market average.
| 1.22 |
| 116.67% |
| 2.11 |
| 2.08 |
| 63.51 |
| 1,437,456 |
Income Statement
In the last 12 months, Compass Therapeutics had revenue of 850K and earned -49.38M in profits. Earnings per share was 0.
| 850K |
| 850K |
| -56.63M |
| -49.38M |
| -54.87M |
| -56.63M |
| 0 |
Balance Sheet
The company has 43.48M in cash and 6.63M in debt, giving a net cash position of 36.85M.
| 43.48M |
| 6.63M |
| 36.85M |
| -364.68M |
| 131.45M |
| 109.25M |
Cash Flow
In the last 12 months, operating cash flow was -44.85M and capital expenditures -44K, giving a free cash flow of -44.9M.
| -44.85M |
| -44K |
| -44.9M |
| 0 |
Margins
Gross margin is 100%, with operating and profit margins of -6661.76% and -5808.82%.
| 100% |
| -6661.76% |
| -5808.82% |
| -5808.82% |
| -6455.53% |
| -6661.76% |
| -5282.24% |
Dividends & Yields
CMPX does not appear to pay any dividends at this time.
| n/a |
| n/a |
| n/a |
| n/a |
| n/a |
| n/a |
Analyst Forecast
The average price target for CMPX is $8, which is 207.7% higher than the current price. The consensus rating is "Buy".
| $8 |
| 207.7% |
| Buy |
| 8 |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| n/a |
| -100% |
| n/a |
| n/a |
Scores
| 5.34 |
| 3 |